The UK and US have forged a major trade agreement that will ensure zero tariffs on British drug exports entering the American market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to raise funding on drugs through the National Health Service (NHS). This move secures that duties on these crucial goods will stay at zero for a timeframe of the next three years.
This development comes after earlier warnings to dramatically increase import taxes on patented pharmaceutical imports, with figures mentioned reaching 100%.
"This arrangement with the United Kingdom strengthens the worldwide climate for cutting-edge drugs and introduces much-needed balance to transatlantic drug exports," a statement said.
Economic Significance
Drugs are one of the the United Kingdom's most significant exports to the United States, which is easily the biggest buyer for leading British pharmaceutical firms.
Trade data indicate that in the one-year period leading up to the third quarter, the UK exported medicines valued at £11.1bn to the US. This figure represented 17.4% of British export trade in that span.
"This agreement secures employment, increases capital expenditure and sets the stage for the UK to establish itself as a worldwide center for medical research," a minister remarked.
Detailed British Pledges
The deal involves several key changes from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it judges new therapies to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a aim to increase total public funding on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum manufacturers must pay back to the NHS to prevent overspending will be capped at fifteen percent. Previously, repayments exceeded twenty percent.
Industry Background
The deal takes place against a protracted row between the sector and the UK government over drug pricing and NHS adoption.
This friction were exacerbated by assertions that American consumers were paying several times more for the same drugs than consumers in the UK and Europe.
Recently, several major drug company projects in the UK have been delayed or scrapped, while multi-billion-dollar funding commitments have been pledged toward US facilities.
The Science Minister publicly accepted that the NHS had to invest a greater share on medicines, noting that its spending on drugs had decreased as a share of its overall budget over the past decade.
